{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:36:22Z","timestamp":1771486582458,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04182-2","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T02:09:06Z","timestamp":1738634946000},"page":"682-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The potential role of neoadjuvant treatment in thyroid cancers in the era of kinase inhibitors: a narrative review"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-7178","authenticated-orcid":false,"given":"D.","family":"Barbaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Giani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Profilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Forleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rosada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Basili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Materazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"4182_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/JHC.S357313","volume":"9","author":"Z Yin","year":"2022","unstructured":"Z. Yin, D. Chen, S. Liang, X. Li, Neoadjuvant therapy for hepatocellular carcinoma. J. Hepatocell. Carcinoma 9, 929\u2013946 (2022)","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"3","key":"4182_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4274\/ejbh.galenos.2024.2023-12-16","volume":"20","author":"AS Qari","year":"2024","unstructured":"A.S. Qari, A.H. Mowais, S.M. Alharbi, M.J. Almuayrifi, A.A. Al Asiri, S.A. Alwatid, A.A. Aljohani, R.M. Alanazi, F. Al Thoubaity, Adjuvant and neoadjuvant therapy for breast cancer: a systematic review. Eur J Breast Heal 20(3), 156\u2013166 (2024)","journal-title":"Eur J Breast Heal"},{"issue":"5","key":"4182_CR3","first-page":"43","volume":"18","author":"Y Al-Khazraji","year":"2024","unstructured":"Y. Al-Khazraji, M.A. Muzammil, S. Javid, A.V. Tangella, N.V. Gohil, H. Saifullah, S.G. Kanagala, F. Fariha, A. Muneer, S. Ahmed, A. Shariq, Novel regimens and treatment strategies in neoadjuvant therapy for colorectal cancer: a systematic review. Int J Heal. Sci 18(5), 43\u201358 (2024)","journal-title":"Int J Heal. Sci"},{"key":"4182_CR4","first-page":"3743420","volume":"2016","author":"RP Dang","year":"2016","unstructured":"R.P. Dang, D. McFarland, V.H. Le, N. Camille, B.A. Miles, M.S. Teng, E.M. Genden, K.J. Misiukiewicz, Neoadjuvant therapy in differentiated thyroid cancer. Int. J. Surg. Oncol. 2016, 3743420 (2016)","journal-title":"Int. J. Surg. Oncol."},{"key":"4182_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"4182_CR6","doi-asserted-by":"publisher","first-page":"1064472","DOI":"10.3389\/fphar.2022.1064472","volume":"13","author":"RR Naik","year":"2023","unstructured":"R.R. Naik, A.K. Shakya, Exploring the chemotherapeutic potential of currently used kinase inhibitors: an update. Front. Pharmacol. 13, 1064472 (2023). https:\/\/doi.org\/10.3389\/fphar.2022.1064472","journal-title":"Front. Pharmacol."},{"issue":"7","key":"4182_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.-B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621\u2013630 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"4182_CR8","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"R. Elisei, M.J. Schlumberger, S.P. M\u00fcller, P. Sch\u00f6ffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl, B. Niederle, E.E.W. Cohen, L.J. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, S.I. Sherman, Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31(29), 3639\u20133646 (2013)","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"4182_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"S.A. Wells, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, Vasselli JR, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30(2), 134\u2013141 (2012)","journal-title":"J. Clin. Oncol."},{"issue":"9940","key":"4182_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W.A. Smit, J. Chung, C. Kappeler, C. Pe\u00f1a, I. Moln\u00e1r, M.J. Schlumberger, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940), 319\u2013328 (2014)","journal-title":"Lancet"},{"issue":"7","key":"4182_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"M.F. Mosele, C.B. Westphalen, A. Stenzinger, F. Barlesi, A. Bayle, I. Bi\u00e8che, J. Bonastre, E. Castro, R. Dienstmann, A. Kr\u00e4mer, A.M. Czarnecka, F. Meric-Bernstam, S. Michiels, R. Miller, N. Normanno, J. Reis-Filho, J. Remon, M. Robson, E. Rouleau, A. Scarpa, C. Serrano, J. Mateo, F. Andr\u00e9, Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol 35(7), 588\u2013606 (2024)","journal-title":"Ann Oncol"},{"issue":"7","key":"4182_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hed.23406","volume":"36","author":"DM Hartl","year":"2014","unstructured":"D.M. Hartl, S. Zago, S. Leboulleux, H. Mirghani, D. D\u00e9andreis, E. Baudin, M. Schlumberger, Resection margins and prognosis in locally invasive thyroid cancer. Head Neck 36(7), 1034\u20131038 (2014)","journal-title":"Head Neck"},{"issue":"3","key":"4182_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark, A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3), 337\u2013386 (2021)","journal-title":"Thyroid"},{"issue":"1","key":"4182_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Z.W. Baloch, S.L. Asa, J.A. Barletta, R.A. Ghossein, C.C. Juhlin, C.K. Jung, V.A. LiVolsi, M.G. Papotti, M. Sobrinho-Sim\u00f5es, G. Tallini, O. Mete, Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33(1), 27\u201363 (2022)","journal-title":"Endocr. Pathol."},{"key":"4182_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijscr.2017.10.010","volume":"41","author":"M Tsuboi","year":"2017","unstructured":"M. Tsuboi, H. Takizawa, M. Aoyama, A. Tangoku, Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int. J. Surg. Case Rep. 41, 89\u201392 (2017)","journal-title":"Int. J. Surg. Case Rep."},{"issue":"3","key":"4182_CR16","first-page":"370","volume":"62","author":"DLS Danilovic","year":"2018","unstructured":"D.L.S. Danilovic, G. Castro, F.S.R. Roitberg, F.A.B. Vanderlei, F.A. Bonani, R.M.C. Freitas, G.B. Coura-Filho, R.Y. Camargo, M.A. Kulcsar, S. Marui, A.O. Hoff, Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch. Endocrinol. Metab. 62(3), 370\u2013375 (2018)","journal-title":"Arch. Endocrinol. Metab."},{"issue":"2","key":"4182_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000494880","volume":"8","author":"KE Stewart","year":"2019","unstructured":"K.E. Stewart, M.W.J. Strachan, D. Srinivasan, M. Macneill, L. Wall, I.J. Nixon, Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur. Thyroid J. 8(2), 102\u2013107 (2019)","journal-title":"Eur. Thyroid J."},{"issue":"24s","key":"4182_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2019-0099","volume":"15","author":"S Gay","year":"2019","unstructured":"S. Gay, E. Monti, C. Trambaiolo Antonelli, M. Mora, B. Spina, G. Ansaldo, M. Teliti, M. Comina, L. Conte, M. Minuto, E. Varaldo, S. Zupo, B. Massa, S. Morbelli, M. Giusti, Case report: Lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Futur. Oncol. 15(24s), 13\u201319 (2019)","journal-title":"Futur. Oncol."},{"issue":"7","key":"4182_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1089\/thy.2018.0060","volume":"28","author":"ME Cabanillas","year":"2018","unstructured":"M.E. Cabanillas, R. Ferrarotto, A.S. Garden, S. Ahmed, N.L. Busaidy, R. Dadu, M.D. Williams, H. Skinner, G.B. Gunn, H. Grosu, P. Iyer, M.C. Hofmann, M. Zafereo, Neoadjuvant BRAF-and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7), 945\u2013951 (2018)","journal-title":"Thyroid"},{"issue":"12","key":"4182_CR20","doi-asserted-by":"publisher","first-page":"e236934","DOI":"10.1136\/bcr-2020-236934","volume":"13","author":"D Barbaro","year":"2020","unstructured":"D. Barbaro, P. Lapi, P. Viacava, L. Torregrossa, Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Rep 13(12), e236934 (2020). https:\/\/doi.org\/10.1136\/bcr-2020-236934","journal-title":"BMJ Case Rep"},{"key":"4182_CR21","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.athoracsur.2022.04.034","volume":"115","author":"J Kent","year":"2023","unstructured":"J. Kent, P. Erwin, D. Haraf, C.Y. Liao, J. Durham, P. Angelos, N. Agrawal, B.J. Baird, M.L.L. Madariaga, Laryngotracheal resection after B-Raf proto-oncogene inhibition for anaplastic thyroid carcinoma. Annals of Thoracic Surgery 115, e117\u2013e120 (2023)","journal-title":"Annals of Thoracic Surgery"},{"issue":"1","key":"4182_CR22","first-page":"e220179","volume":"12","author":"I Dam\u00e1sio","year":"2022","unstructured":"I. Dam\u00e1sio, J. Sim\u00f5es-Pereira, S. Donato, M. Horta, B.M. Cavaco, M. Rito, P. Gomes, V. Leite, Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. Eur Thyroid J 12(1), e220179 (2022)","journal-title":"Eur Thyroid J"},{"issue":"3","key":"4182_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00405-023-07827-y","volume":"280","author":"E Maurer","year":"2023","unstructured":"E. Maurer, F. Eilsberger, S. W\u00e4chter, J. Riera Knorrenschild, A. Pehl, K. Holzer, A. Neubauer, M. Luster, D.K. Bartsch, Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur. Arch. Oto-Rhino-Laryngology 280(3), 1509\u20131518 (2023)","journal-title":"Eur. Arch. Oto-Rhino-Laryngology"},{"issue":"2","key":"4182_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ22-0366","volume":"70","author":"Y Song","year":"2023","unstructured":"Y. Song, Y. Bai, J. Wang, G. Xu, T. Wang, B. Zhang, Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review. Endocr. J. 70(2), 223\u2013228 (2023)","journal-title":"Endocr. J."},{"issue":"23","key":"4182_CR25","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1200\/JCO.2009.27.4225","volume":"28","author":"JM Cleary","year":"2010","unstructured":"J.M. Cleary, P.M. Sadow, G.W. Randolph, E.L. Palmer, T.P. Lynch, Y.E. Nikiforov, L.J. Wirth, Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J. Clin. Oncol. 28(23), e390\u2013e392 (2010). https:\/\/doi.org\/10.1200\/JCO.2009.27.4225","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"4182_CR26","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.4158\/ACCR-2019-0365","volume":"6","author":"H Golingan","year":"2020","unstructured":"H. Golingan, B. Hunis, A.C. Golding, D.N. Bimston, R.M. Harrell, Neoadjuvant lenvatinib in advanced unresectable medullary thyroid carcinoma: a case report. AACE Clin. Case Reports 6(2), e73\u2013e78 (2020)","journal-title":"AACE Clin. Case Reports"},{"issue":"1","key":"4182_CR27","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/hed.26527","volume":"43","author":"Y Jozaghi","year":"2021","unstructured":"Y. Jozaghi, M. Zafereo, M.D. Williams, M.K. Gule-Monroe, J. Wang, E.G. Grubbs, A. Vaporciyan, M.I. Hu, N. Busaidy, R. Dadu, S.G. Waguespack, V. Subbiah, M. Cabanillas, Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43(1), E7\u2013E12 (2021)","journal-title":"Head Neck"},{"key":"4182_CR28","doi-asserted-by":"publisher","first-page":"e2300257","DOI":"10.1200\/po.23.00257","volume":"8","author":"R Kothari","year":"2024","unstructured":"R. Kothari, S. Kreimer, H. Nadel, H. Seeley, G. Hartman, K.D. Meister, Use of neoadjuvant vandetanib in aggressive pediatric medullary thyroid carcinoma. JCO Precis. Oncol. 8, e2300257 (2024). https:\/\/doi.org\/10.1200\/po.23.00257","journal-title":"JCO Precis. Oncol."},{"key":"4182_CR29","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fendo.2019.00712","volume":"10","author":"CF Nava","year":"2019","unstructured":"C.F. Nava, R.S. Scheffel, A.P. Cristo, C.V. Ferreira, S. Weber, A.B. Zanella, F.C. Paix\u00e3o, A. Migliavaca, J.R. Guimar\u00e3es, M.S. Graudenz, J.M. Dora, A.L. Maia, Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma. Front. Endocrinol. (Lausanne). 10, 712 (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00712","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"1","key":"4182_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/thy.2022.0506","volume":"33","author":"KJ Contrera","year":"2023","unstructured":"K.J. Contrera, M.K. Gule-Monroe, M.I. Hu, M.E. Cabanillas, N.L. Busaidy, R. Dadu, S.G. Waguespack, J.R. Wang, A. Maniakas, S.Y. Lai, J. Diersing, M. Kwon, E.G. Grubbs, V. Subbiah, M.D. Williams, M.E. Zafereo, Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series. Thyroid 33(1), 129\u2013132 (2023)","journal-title":"Thyroid"},{"key":"4182_CR31","doi-asserted-by":"publisher","first-page":"1389294","DOI":"10.3389\/fendo.2024.1389294","volume":"15","author":"D Barbaro","year":"2024","unstructured":"D. Barbaro, R. Forleo, M.A. Profilo, P. Lapi, C. Giani, L. Torregrossa, E. Macerola, G. Materazzi, Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report. Front Endocrinol 15, 1389294 (2024)","journal-title":"Front Endocrinol"},{"key":"4182_CR32","doi-asserted-by":"publisher","first-page":"6438352","DOI":"10.1155\/2020\/6438352","volume":"2020","author":"H Iwasaki","year":"2020","unstructured":"H. Iwasaki, S. Toda, H. Ito, D. Nemoto, D. Murayama, Y. Okubo, H. Hayashi, T. Yokose, A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep. Endocrinol. 2020, 6438352 (2020). https:\/\/doi.org\/10.1155\/2020\/6438352","journal-title":"Case Rep. Endocrinol."},{"issue":"12","key":"4182_CR33","first-page":"E25191","volume":"100","author":"Y Zhang","year":"2021","unstructured":"Y. Zhang, X. Deng, Z. Ding, J. Kang, B. Wu, B. Guo, Y. Fan, Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: a case report. Med. (United States) 100(12), E25191 (2021)","journal-title":"Med. (United States)"},{"issue":"6","key":"4182_CR34","doi-asserted-by":"publisher","first-page":"e000659","DOI":"10.20945\/2359-3997000000659","volume":"67","author":"YJ Su","year":"2023","unstructured":"Y.J. Su, S.H. Cheng, J. Qian, M. Zhang, W. Liu, X.X. Zhan, Z.Q. Wang, H.D. Liu, X.W. Zhong, R.C. Cheng, Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAFV600E mutations: a case report. Arch. Endocrinol. Metab. 67(6), e000659 (2023). https:\/\/doi.org\/10.20945\/2359-3997000000659","journal-title":"Arch. Endocrinol. Metab."},{"issue":"2","key":"4182_CR35","doi-asserted-by":"publisher","first-page":"e1466","DOI":"10.1002\/cnr2.1466","volume":"5","author":"K Alshehri","year":"2022","unstructured":"K. Alshehri, Y. Alqurashi, M. Merdad, S. Samargandy, R. Daghistani, H. Marzouki, Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review. Cancer Rep 5(2), e1466 (2022). https:\/\/doi.org\/10.1002\/cnr2.1466","journal-title":"Cancer Rep"},{"issue":"11","key":"4182_CR36","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1017\/S0022215123000506","volume":"137","author":"JJY Yeo","year":"2023","unstructured":"J.J.Y. Yeo, K. Stewart, P. Maniam, S. Arman, D. Srinivasan, L. Wall, M. MacNeill, M. Strachan, I. Nixon, Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series. J. Laryngol. Otol. 137(11), 1237\u20131243 (2023)","journal-title":"J. Laryngol. Otol."},{"key":"4182_CR37","doi-asserted-by":"publisher","first-page":"106625","DOI":"10.1016\/j.oraloncology.2023.106625","volume":"147","author":"JL Farlow","year":"2023","unstructured":"J.L. Farlow, H.C. McCrary, J.A. Sipos, J.E. Phay, B. Konda, A. Agrawal, Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer. Oral Oncol 147, 106625 (2023). https:\/\/doi.org\/10.1016\/j.oraloncology.2023.106625","journal-title":"Oral Oncol"},{"issue":"8","key":"4182_CR38","doi-asserted-by":"publisher","first-page":"uae112","DOI":"10.1210\/jcemcr\/luae112","volume":"2","author":"N Bapat","year":"2024","unstructured":"N. Bapat, T. Ferraro, L. Esper, A.S. Joshi, F. Haroun, C.K. Baldwin, Treatment of unresectable BRAF V600E, TERT-mutated differentiated papillary thyroid cancer with dabrafenib and trametinib. JCEM Case Rep 2(8), uae112 (2024)","journal-title":"JCEM Case Rep"},{"key":"4182_CR39","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/hed.27735","volume":"46","author":"M Russell","year":"2024","unstructured":"M. Russell, M.L. Gild, L.J. Wirth, B. Robinson, A.S. Karcioglu, A. Iwata, T.S. Athni, A.H. Abdelhamid Ahmed, G.W. Randolph, Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience. Head Neck 46, 2496\u20132507 (2024). https:\/\/doi.org\/10.1002\/hed.27735","journal-title":"Head Neck"},{"issue":"4","key":"4182_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"X. Zhao, J.R. Wang, R. Dadu, N.L. Busaidy, L. Xu, K.O. Learned, N.N. Chasen, T. Vu, A. Maniakas, A.A. Eguia, J. Diersing, N.D. Gross, R. Goepfert, S.Y. Lai, M.-C. Hofmann, R. Ferrarotto, C. Lu, G.B. Gunn, M.T. Spiotto, V. Subbiah, M.D. Williams, M.E. Cabanillas, M.E. Zafereo, Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid 33(4), 484\u2013491 (2023)","journal-title":"Thyroid"},{"issue":"3","key":"4182_CR41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"S. Hamidi, P.C. Iyer, R. Dadu, M.K. Gule-Monroe, A. Maniakas, M.E. Zafereo, J.R. Wang, N.L. Busaidy, M.E. Cabanillas, Checkpoint inhibition in addition to Dabrafenib\/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 34(3), 336\u2013346 (2024)","journal-title":"Thyroid"},{"issue":"7","key":"4182_CR42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1089\/thy.2024.0090","volume":"34","author":"F Pitoia","year":"2024","unstructured":"F. Pitoia, E. Abelleira, A. Rom\u00e1n-Gonz\u00e1lez, D.L.S. Danilovic, R. Selbach Scheffel, A.L. Maia, A.O. Hoff, I. Califano, Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary latin american experience. Thyroid 34(7), 949\u2013952 (2024)","journal-title":"Thyroid"},{"issue":"20","key":"4182_CR43","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","volume":"29","author":"Y Chi","year":"2023","unstructured":"Y. Chi, X. Zheng, Y. Zhang, F. Shi, Y. Cheng, Z. Guo, M. Ge, J. Qin, J. Zhang, Z. Li, X. Zhou, R. Huang, X. Chen, H. Liu, R. Cheng, Z. Xu, D. Li, P. Tang, M. Gao, Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial. Clin. Cancer Res. 29(20), 4047\u20134056 (2023)","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"4182_CR44","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"D. Li, Y. Chi, X. Chen, M. Ge, Y. Zhang, Z. Guo, J. Wang, J. Chen, J. Zhang, Y. Cheng, Z. Li, H. Liu, J. Qin, J. Zhu, R. Cheng, Z. Xu, X. Zheng, P. Tang, M. Gao, Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin. Cancer Res. 27(13), 3567\u20133575 (2021)","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"4182_CR45","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1089\/thy.2021.0307","volume":"31","author":"NS Huang","year":"2021","unstructured":"N.S. Huang, W.J. Wei, J. Xiang, J.Y. Chen, Q. Guan, Z.W. Lu, B. Ma, G.H. Sun, Y.L. Wang, Q.H. Ji, Y. Wang, The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase II clinical trial. Thyroid 31(12), 1808\u20131813 (2021)","journal-title":"Thyroid"},{"issue":"12","key":"4182_CR46","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.1245\/s10434-023-14031-z","volume":"30","author":"JY Chen","year":"2023","unstructured":"J.Y. Chen, N.S. Huang, W.J. Wei, J.Q. Hu, Y.M. Cao, Q. Shen, Z.W. Lu, Y.L. Wang, Y. Wang, Q.H. Ji, The efficacy and safety of surufatinib combined with anti PD-1 antibody toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: a phase II study. Ann. Surg. Oncol. 30(12), 7172\u20137180 (2023)","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"4182_CR47","doi-asserted-by":"publisher","first-page":"znae199","DOI":"10.1093\/bjs\/znae199","volume":"111","author":"M Raffaelli","year":"2024","unstructured":"M. Raffaelli, N. Voloudakis, M. Barczynski, K. Brauckhoff, C. Durante, J. Gomez-Ramirez, I. Koutelidakis, K. Lorenz, O. Makay, G. Materazzi, R. Pandev, G.W. Randolph, N. Tolley, M. Vriens, T. Musholt, European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management. Br. J. Surg. 111(8), znae199 (2024)","journal-title":"Br. J. Surg."},{"issue":"10","key":"4182_CR48","first-page":"1184","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"N.L. Busaidy, B. Konda, L. Wei, L.J. Wirth, C. Devine, G.A. Daniels, J.A. Desouza, M. Poi, N.D. Seligson, M.E. Cabanillas, J.A. Sipos, M.D. Ringel, A.K. Eisfeld, C. Timmers, M.H. Shah, Dabrafenib versus Dabrafenib + Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32(10), 1184\u20131192 (2022)","journal-title":"Thyroid"},{"issue":"9","key":"4182_CR49","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"MS Brose","year":"2016","unstructured":"M.S. Brose, M.E. Cabanillas, E.E.W. Cohen, L.J. Wirth, T. Riehl, H. Yue, S.I. Sherman, E.J. Sherman, Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9), 1272\u20131282 (2016)","journal-title":"Lancet Oncol"},{"key":"4182_CR50","doi-asserted-by":"publisher","first-page":"712107","DOI":"10.3389\/fendo.2021.712107","volume":"12","author":"P Adam","year":"2021","unstructured":"P. Adam, S. Kircher, I. Sbiera, V.F. Koehler, E. Berg, T. Kn\u00f6sel, B. Sandner, W.K. Fenske, H. Bl\u00e4ker, C. Smaxwil, A. Zielke, B. Sipos, S. Allelein, M. Schott, C. Dierks, C. Spitzweg, M. Fassnacht, M. Kroiss, FGF-Receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale. Front. Endocrinol. (Lausanne). 12, 712107 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.712107","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"17","key":"4182_CR51","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","volume":"30","author":"JD French","year":"2024","unstructured":"J.D. French, B.R. Haugen, F.P. Worden, D.W. Bowles, A.G. Gianoukakis, B. Konda, R. Dadu, E.J. Sherman, S. McCue, N.R. Foster, Y.E. Nikiforov, T.D.J. Farias, P.J. Norman, L.J. Wirth, Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin. Cancer Res. 30(17), 3757\u20133767 (2024)","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"4182_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21037\/cco-23-133","volume":"13","author":"A Pinheiro Neto","year":"2024","unstructured":"A. Pinheiro Neto, H.L. Lucchesi, V.A. Dos Santos Valsecchi, L. Sterian Ward, L. Leite Cunha, Immunotherapy for patients with thyroid cancer: a comprehensive appraisal. Chin Clin Oncol 13(3), 36 (2024). https:\/\/doi.org\/10.21037\/cco-23-133","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"4182_CR53","doi-asserted-by":"publisher","first-page":"e081090","DOI":"10.1136\/bmjopen-2023-081090","volume":"14","author":"J Yu","year":"2024","unstructured":"J. Yu, H. Liu, Y. Wu, Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China. BMJ Open 14(5), e081090 (2024)","journal-title":"BMJ Open"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04182-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04182-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04182-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:05:05Z","timestamp":1749215105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04182-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4182"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04182-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}